Should you get an APOE gene test? What a result actually changes

Short answer: For most people, no — but the standard advice you'll find online is now out of date, and the reason to think twice has changed. APOE isn't a diagnosis: the common variant raises your risk without determining your future, and plenty of carriers never develop dementia. What's new is that there is finally one situation where the result genuinely guides medical care, and one piece of good news for carriers that almost nobody mentions. There's also one practical consequence — insurance — that the top search results skip entirely, and it's the thing most likely to affect your life. Before you order a test, it's worth knowing all three.

This is educational, not medical advice. Genetic testing decisions belong in a conversation with your doctor or a certified genetic counsellor, who can look at your actual family history. If you're worried about memory changes that are new, worsening, and affecting daily life, that warrants a clinical appointment regardless of any gene test.

What APOE actually is

Everyone carries two copies of the APOE gene, one from each parent, and each copy comes in one of three common versions: ε2, ε3 or ε4.

• ε3 is the most common and is considered risk-neutral.
• ε2 appears to be modestly protective.
• ε4 is the version associated with higher Alzheimer's risk — and the one every test is really selling.

Roughly 15–25% of people carry one copy of ε4, and about 2–5% carry two. One copy raises risk. Two copies raise it a great deal more.

The crucial distinction — and the one that causes the most unnecessary fear — is between a risk gene and a deterministic gene. A handful of rare mutations (APP, PSEN1, PSEN2) essentially guarantee early-onset Alzheimer's, usually before 65, and they account for well under 1% of cases. APOE4 is not one of them. It shifts the odds. It does not write the ending. People with two copies reach their 80s without dementia, and most people who develop Alzheimer's are not ε4 homozygotes at all.

If you want the wider picture of what family history does and doesn't pass down, we've covered that in is dementia hereditary? and is dementia inherited from your mother or father?

The exception worth knowing: two copies

There's a real nuance here that consumer articles tend to flatten. In 2024, a study in Nature Medicine examined postmortem brain pathology from more than 3,200 people plus biomarker data, and argued that carrying two copies of ε4 looks less like elevated risk and more like a distinct genetic form of Alzheimer's disease in its own right.

The findings behind that claim:

• Nearly all ε4 homozygotes in the dataset showed Alzheimer's brain pathology from age 55 onward
• They showed consistently high levels of Alzheimer's biomarkers starting around the same age
• ε4 homozygotes are about 2% of the population but roughly 15% of Alzheimer's cases
• Estimated ~60% chance of developing Alzheimer's dementia by age 85

Read that carefully, because it cuts both ways. It's a serious finding for a small group — and 60% by 85 is not 100%. Even in the highest-risk genotype known, a substantial share of people do not develop dementia. And for the far larger group with a single ε4 copy, none of this applies directly.

The one situation where the result now changes medical care

Here's what's changed, and why the "don't bother testing, nothing can be done" answer you'll read on pages written a few years ago is no longer complete.

The anti-amyloid drugs lecanemab and donanemab are now approved for early Alzheimer's disease. Their FDA labels recommend APOE genotyping before starting treatment — not to decide whether the drug works, but because of a side effect called ARIA (amyloid-related imaging abnormalities: brain swelling and small bleeds visible on MRI). ARIA risk rises with ε4 dose, and is highest in people carrying two copies.

So genotype now informs a genuine clinical conversation — about whether the benefit of one of these drugs outweighs its risk for a particular person.

But note who that applies to. This matters for someone already diagnosed with early Alzheimer's or mild cognitive impairment who is considering one of these treatments. In that situation the testing is arranged by the treating clinician as part of the decision. It is not a reason for a healthy 52-year-old to order a mail-in kit — knowing your genotype years in advance doesn't make you eligible for anything, and no anti-amyloid drug is approved for people without symptoms. If you're weighing this, the person to ask is the prescribing neurologist, not a testing company.

The good news nobody puts in the headline

If you already know you carry ε4 — or you're bracing for that result — this is the finding worth holding on to.

A meta-analysis published in Alzheimer's & Dementia in December 2025 pooled three randomised controlled trials of multidomain lifestyle intervention — FINGER in Finland (1,109 participants with APOE data), J-MINT in Japan (426) and MAPT in France (934). These were structured programmes combining exercise, diet, cognitive training and vascular risk monitoring.

The result: ε4 carriers got more cognitive benefit from the intervention than non-carriers (interaction p = 0.035), a pattern that held across all three trials. The authors describe the evidence as preliminary, and it deserves that caution — three trials, differing designs, modest effect sizes.

Still, the direction is the opposite of the fatalism most people bring to a positive result. The group with the most to worry about genetically may have the most to gain from getting the modifiable factors right. Your genotype is fixed. Your blood pressure, hearing, activity, sleep and blood sugar are not — and they appear to matter more, not less, if you carry ε4. That is also why we'd point you at what midlife blood pressure, diabetes and smoking cost you in dementia-free years before we'd point you at a saliva kit.

The consequence the top search results skip: insurance

This is the most practically important thing on this page, and it's missing from nearly every article that ranks for this question.

In the US, GINA — the Genetic Information Nondiscrimination Act — protects you in two areas only: health insurance and employment. It does not cover:

• Life insurance
• Long-term care insurance
• Disability insurance

In most states, insurers in those three categories may lawfully ask about genetic test results and use them in underwriting. Some states have passed broader protections, so the picture depends on where you live.

The irony is sharp: long-term care insurance is exactly the product someone worried about dementia would want, and it's one of the categories GINA doesn't reach. Many genetic counsellors therefore suggest that if you're considering both, you think about the sequence — and about the fact that a result, once it exists in your records, cannot be un-known. If insurance matters to your situation, raise it with a genetic counsellor before testing, not after.

And if you're thinking about a direct-to-consumer kit

Two things to weigh beyond the price.

A result with no one to explain it. Clinical testing comes with counselling before and after. A mail-in kit typically delivers a genotype to a dashboard. For a result with this much emotional weight and this much room for misreading, that gap is the whole problem.

Your genetic data is an asset that can change hands. In March 2025, 23andMe filed for bankruptcy, putting the genetic data of more than 15 million people into a court process. A judge ultimately approved the sale of the database for $305 million to TTAM Research Institute, a nonprofit led by co-founder Anne Wojcicki. That outcome was better than many feared. The lesson stands anyway: when you hand your genome to a company, you're also betting on that company's future. Read the deletion policy before you spit in the tube, not after.

So — should you get tested?

A reasonable way to think it through.

Testing may be worth discussing if:

• You have a strong family history of early-onset dementia (before 65), which raises the question of the rare deterministic genes rather than APOE
• You've been diagnosed with mild cognitive impairment or early Alzheimer's and are considering anti-amyloid treatment — here your clinician will usually arrange it
• You're joining a clinical trial that requires genotype
• You've thought hard about it, have a counsellor lined up, have checked the insurance implications, and genuinely want to know

Testing is probably not worth it if:

• You want reassurance — a negative result doesn't remove your risk, and most dementia occurs in non-carriers
• You're hoping it will tell you what to do — the actions are the same either way, and we know what they are
• You haven't checked how it interacts with life, disability or long-term-care insurance
• You'd be doing it instead of addressing the modifiable factors, rather than alongside them

Being straight about our own interest: we build a free risk-factor profile, so we have an obvious incentive to tell you that modifiable factors matter more than genes. Weigh that. The sources below are there so you can check the claims rather than take our word for it — and our honest read is that for most people this test changes anxiety more than it changes decisions.

The part you can actually act on

Whatever you decide about testing, the evidence points somewhere consistent: the modifiable factors are where the leverage is, and they may matter most for the people at highest genetic risk.

That's not a consolation prize. It's the finding.

How we research and review our content →

This article is educational and is not medical advice, diagnosis, or treatment. The studies cited describe findings in general populations, not Solenna specifically. The 2024 Nature Medicine analysis describes risk within a genotype group and does not predict any individual's outcome; the December 2025 meta-analysis is described by its own authors as preliminary. Nothing here is guidance on whether to undergo genetic testing, whether to take or avoid any medication, or how to arrange insurance — those are decisions for you together with a qualified clinician or certified genetic counsellor. Solenna is not a medical device and does not diagnose, prevent, treat, or cure Alzheimer's disease or any other condition. Risk reduction means lowering probability, not eliminating it; individual results vary and no outcome is guaranteed.